Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP

Valeria Bonfante, Armando Santoro, Simonetta Viviani, Roberto Zucali, Liliana Devizzi, Marcello Zanini, John David Tesoro Tess, Pinuccia Valagussa, Alberto Banfi, Gianni Bonadonna

Research output: Contribution to journalArticle

Abstract

From September 1976 to June 1982, 201 consecutive patients with stage I (A and B)-IIA Hodgkin's disease were stratified in two groups according to prognostic factors. The F group included 116 patients with favourable presentation: they were staged with laparotomy and treated with subtotal or total nodal radiotherapy alone. The U group included 85 cases with unfavourable presentation who were staged by laparoscopy and treated with 3MOPP (mechlorethamine, vincristine, procarbazine, prednisone)-radiotherapy-3MOPP. At 10 years the F group showed a freedom from progression (FFP) of 71%, with significant difference between stage I and II (85% vs. 59%; P=0.003) and an overall survival of 84%. The results of the U group were: FFP 83%, overall survival 74%, and the findings were not influenced by stage. FFP in patients with bulky vs. not bulky lymphoma was 70% vs. 87% (P=0.04). No secondary acute non-lymphocytic leukaemia developed among patients treated with radiotherapy and in continuous complete remission, while acute leukaemia occurred in the F group patients who received salvage chemotherapy (4 of 31 cases) and in the U group (3 of 85 cases). Present results confirm the usefulness of radiotherapy alone in favourable pathological stage IA. All other disease stages will require a different strategy that should consist of radiotherapy combined with short-term effective regimens, such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or VBM (vinblastine, bleomycin and methotrexate) to reduce the incidence of MOPP-associated gonadal dysfunction and leukaemogenesis.

Original languageEnglish
Pages (from-to)24-29
Number of pages6
JournalEuropean Journal of Cancer
Volume29
Issue number1
DOIs
Publication statusPublished - 1993

Fingerprint

Hodgkin Disease
Radiotherapy
Vinblastine
Bleomycin
Procarbazine
Mechlorethamine
Dacarbazine
Survival
Vincristine
Prednisone
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Laparoscopy
Doxorubicin
Laparotomy
Lymphoma
Leukemia
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Early stage Hodgkin's disease : Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. / Bonfante, Valeria; Santoro, Armando; Viviani, Simonetta; Zucali, Roberto; Devizzi, Liliana; Zanini, Marcello; Tess, John David Tesoro; Valagussa, Pinuccia; Banfi, Alberto; Bonadonna, Gianni.

In: European Journal of Cancer, Vol. 29, No. 1, 1993, p. 24-29.

Research output: Contribution to journalArticle

Bonfante, Valeria ; Santoro, Armando ; Viviani, Simonetta ; Zucali, Roberto ; Devizzi, Liliana ; Zanini, Marcello ; Tess, John David Tesoro ; Valagussa, Pinuccia ; Banfi, Alberto ; Bonadonna, Gianni. / Early stage Hodgkin's disease : Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. In: European Journal of Cancer. 1993 ; Vol. 29, No. 1. pp. 24-29.
@article{278fde76824447eab511ae4ccc86e9f2,
title = "Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP",
abstract = "From September 1976 to June 1982, 201 consecutive patients with stage I (A and B)-IIA Hodgkin's disease were stratified in two groups according to prognostic factors. The F group included 116 patients with favourable presentation: they were staged with laparotomy and treated with subtotal or total nodal radiotherapy alone. The U group included 85 cases with unfavourable presentation who were staged by laparoscopy and treated with 3MOPP (mechlorethamine, vincristine, procarbazine, prednisone)-radiotherapy-3MOPP. At 10 years the F group showed a freedom from progression (FFP) of 71{\%}, with significant difference between stage I and II (85{\%} vs. 59{\%}; P=0.003) and an overall survival of 84{\%}. The results of the U group were: FFP 83{\%}, overall survival 74{\%}, and the findings were not influenced by stage. FFP in patients with bulky vs. not bulky lymphoma was 70{\%} vs. 87{\%} (P=0.04). No secondary acute non-lymphocytic leukaemia developed among patients treated with radiotherapy and in continuous complete remission, while acute leukaemia occurred in the F group patients who received salvage chemotherapy (4 of 31 cases) and in the U group (3 of 85 cases). Present results confirm the usefulness of radiotherapy alone in favourable pathological stage IA. All other disease stages will require a different strategy that should consist of radiotherapy combined with short-term effective regimens, such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or VBM (vinblastine, bleomycin and methotrexate) to reduce the incidence of MOPP-associated gonadal dysfunction and leukaemogenesis.",
author = "Valeria Bonfante and Armando Santoro and Simonetta Viviani and Roberto Zucali and Liliana Devizzi and Marcello Zanini and Tess, {John David Tesoro} and Pinuccia Valagussa and Alberto Banfi and Gianni Bonadonna",
year = "1993",
doi = "10.1016/0959-8049(93)90570-6",
language = "English",
volume = "29",
pages = "24--29",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - Early stage Hodgkin's disease

T2 - Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP

AU - Bonfante, Valeria

AU - Santoro, Armando

AU - Viviani, Simonetta

AU - Zucali, Roberto

AU - Devizzi, Liliana

AU - Zanini, Marcello

AU - Tess, John David Tesoro

AU - Valagussa, Pinuccia

AU - Banfi, Alberto

AU - Bonadonna, Gianni

PY - 1993

Y1 - 1993

N2 - From September 1976 to June 1982, 201 consecutive patients with stage I (A and B)-IIA Hodgkin's disease were stratified in two groups according to prognostic factors. The F group included 116 patients with favourable presentation: they were staged with laparotomy and treated with subtotal or total nodal radiotherapy alone. The U group included 85 cases with unfavourable presentation who were staged by laparoscopy and treated with 3MOPP (mechlorethamine, vincristine, procarbazine, prednisone)-radiotherapy-3MOPP. At 10 years the F group showed a freedom from progression (FFP) of 71%, with significant difference between stage I and II (85% vs. 59%; P=0.003) and an overall survival of 84%. The results of the U group were: FFP 83%, overall survival 74%, and the findings were not influenced by stage. FFP in patients with bulky vs. not bulky lymphoma was 70% vs. 87% (P=0.04). No secondary acute non-lymphocytic leukaemia developed among patients treated with radiotherapy and in continuous complete remission, while acute leukaemia occurred in the F group patients who received salvage chemotherapy (4 of 31 cases) and in the U group (3 of 85 cases). Present results confirm the usefulness of radiotherapy alone in favourable pathological stage IA. All other disease stages will require a different strategy that should consist of radiotherapy combined with short-term effective regimens, such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or VBM (vinblastine, bleomycin and methotrexate) to reduce the incidence of MOPP-associated gonadal dysfunction and leukaemogenesis.

AB - From September 1976 to June 1982, 201 consecutive patients with stage I (A and B)-IIA Hodgkin's disease were stratified in two groups according to prognostic factors. The F group included 116 patients with favourable presentation: they were staged with laparotomy and treated with subtotal or total nodal radiotherapy alone. The U group included 85 cases with unfavourable presentation who were staged by laparoscopy and treated with 3MOPP (mechlorethamine, vincristine, procarbazine, prednisone)-radiotherapy-3MOPP. At 10 years the F group showed a freedom from progression (FFP) of 71%, with significant difference between stage I and II (85% vs. 59%; P=0.003) and an overall survival of 84%. The results of the U group were: FFP 83%, overall survival 74%, and the findings were not influenced by stage. FFP in patients with bulky vs. not bulky lymphoma was 70% vs. 87% (P=0.04). No secondary acute non-lymphocytic leukaemia developed among patients treated with radiotherapy and in continuous complete remission, while acute leukaemia occurred in the F group patients who received salvage chemotherapy (4 of 31 cases) and in the U group (3 of 85 cases). Present results confirm the usefulness of radiotherapy alone in favourable pathological stage IA. All other disease stages will require a different strategy that should consist of radiotherapy combined with short-term effective regimens, such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or VBM (vinblastine, bleomycin and methotrexate) to reduce the incidence of MOPP-associated gonadal dysfunction and leukaemogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0027420187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027420187&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(93)90570-6

DO - 10.1016/0959-8049(93)90570-6

M3 - Article

C2 - 1445741

AN - SCOPUS:0027420187

VL - 29

SP - 24

EP - 29

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -